Vivanza Biosciences Ltd Approves Appointment of Internal Auditor, New Director, and Share Transfer
Vivanza Biosciences Limited announced several key corporate decisions following its Board of Directors meeting held on June 18, 2026. The company approved the appointment of a new internal auditor, welcomed Mr. Hemant Amrish Parikh as an Additional Non-Executive Non-Independent Director, and authorized the transfer of shares from the Unclaimed Suspense Account to a rightful shareholder.Appointment of Internal Auditor
The Board meeting considered and approved the appointment of M/s Dharti Shah & Co. as the Internal Auditor for the Financial Year 2026-2027. This decision followed recommendations by both the Audit Committee and the Nomination & Remuneration Committee.Details regarding the newly appointed auditor are presented below:
| Particular | Details |
|---|---|
| Firm Name | M/s Dharti Shah & Co. |
| Role | Internal Auditor |
| Date of Appointment | June 17, 2026 |
| Term of Appointment | June 17, 2026 to March 31, 2027 |
| Profile Summary | Ms Dharti Shah is a Qualified Chartered Accountant with expertise in strategic audit planning, compliance, and internal controls. |
Director Appointment: Mr. Hemant Amrish Parikh
The Board also considered and approved the appointment of Mr. Hemant Amrish Parikh as an Additional Non-Executive Non-Independent Director. This appointment is effective from June 18, 2026, and subject to approval at the ensuing General Meeting.Mr. Parikh was appointed following a recommendation by the Nomination and Remuneration Committee.
Key details about Mr. Hemant Amrish Parikh are:
| Particular | Details |
|---|---|
| Designation | Additional Non-Executive Non-Independent Director |
| Effective Date | June 18, 2026 |
| Tenure | Up to the upcoming General Meeting (5 years) |
| Professional Background | Chemical Engineer with over 30 years of experience in the pharmaceutical industry. |
Approval for Share Transfer
The directors also considered and approved the transfer of certain unverified shares from the Unclaimed Suspense Account. The transfer involves 300 Equity Shares, which are described as Folio No. N00158 and Certificate Nos. 28496, 28497, and 28498.The approval was granted in favor of Mr. Narendra Jalam Chand Kothari, provided that the rightful shareholder submitted the prescribed KYC documents and other supporting materials, which were subsequently verified by the Company and its Registrar and Share Transfer Agent (RTA). The RTA has been authorized to complete all necessary formalities related to this release and transfer of shares.
Stock Price Movement
As of 10:14, Vivanza Biosciences Ltd. sees shares dipping sharply at ₹1.72, reflecting a 7.53% decline for the day. The stock is currently fluctuating within its intraday range, having moved between a low of ₹1.72 and a high of ₹1.79.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.